neuroendocrine

Graphic image of a red thumbs down against a blue background
Manufacturing

ITM cancer drug spurned by FDA over manufacturing qualms

The problems lie not with ITM-11's efficacy or safety but with its CMC and with a third-party commercial facility.
Darren Incorvaia Aug 10, 2026 11:25am
FDA

FDA recognizes 'crossover impact' on survival in Cabometyx nod

Mar 26, 2025 11:03am
Cancelled

FDA cancels adcomm for Cabometyx in neuroendocrine tumors

Jan 10, 2025 9:46am
FDA

Exelixis' Cabometyx to face FDA adcomm in neuroendocrine tumors

Nov 27, 2024 11:30am
Novartis

With trial win, Novartis eyes first-line use for Lutathera

Sep 25, 2023 10:33am